Inclusion Criteria:
  -  Patients that have a TPP1 enzyme deficiency
  -  Patients have confirmed molecular diagnosis of pathogenic variants in the TPP1 gene
  -  Patients that are enrolled in post-marketing studies will be allowed to enroll into the current study
Exclusion Criteria:
  -  Patients without a diagnosis of CLN2 and deficiency of TPP1
  -  Patients that are currently enrolled as part of a larger multi-center clinical trial